SARS-CoV-2 antigen detection e-Poster now published
Labquality conducted a pilot study for SARS-CoV-2 antigen detection in 2020. Altogether 50 results covering 18 different tests were reported with an average success rate of 99%.
To tackle with the urgent need for EQA for methods detecting SARS-CoV-2, Labquality arranged international EQA pilot studies for both nucleic acid detection and antibody detection in May 2020. These schemes were included Labquality’s program last fall and, in addition, a pilot study for antigen detection was conducted in November.
“The results of the Covid-19 pilot study for antigen detection were excellent and we were very pleased to complete the EQA portfolio for SARS-CoV-2 detection by including this new scheme in our program”, says Labquality’s Development Manager Heidi Berghäll. All three SARS-CoV-2 EQA schemes have received very much positive attention and the number of registered participants from more than 25 different countries is in the hundreds for each of the scheme in 2021.
The first results from the pilot study were presented at the virtual IFCC Global Conference on COVID-19 in February. The study was conducted by Heidi Berghäll, Marsa Järvenpää and Jonna Pelanti (Labquality, Finland) in cooperation with EQA scheme experts Matti Waris (University of Turku, Finland) and Vesa Mäntynen (Nordlab, Finland).
For more information please contact: firstname.lastname@example.org